By Marie Rosenthal
BOSTON—Switching from an HIV regimen containing abacavir, dolutegravir and lamivudine (ABC/DTG/3TC) to one containing bictegravir, emtricitabine and tenofovir alafenamide (BIC/F/TAF) in virologically suppressed adults maintained viral suppression with fewer side effects, according to a presentation at CROI 2018.
In the multicenter randomized, double-blind trial (abstract 22), 563 virologically suppressed adults with HIV taking a regimen of ABC/DTG/3TC (Triumeq, ViiV) were